Newsfeeds Archive - Spark Newswire

2 minute read

Pliant Therapeutics’ Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients

May 14, 10:39 AM

Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis reversal.

PLRX

2 minute read

These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings

By Avi Kapoor

May 7, 11:53 AM

Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted a loss for its first quarter on Monday. Pliant Therapeutics posted a quarterly…

PLRX

4 minute read

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Avi Kapoor

February 5, 1:56 PM

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

$SRM

2 minute read

Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?

By Vandana Singh

February 5, 1:26 PM

Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver fibrosis.

PLRX

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here’s What You Need To Know

By Benzinga Insights

February 5, 1:00 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Pliant Therapeutics (NASDAQ:PLRX) and lower its…

PLRX

2 minute read

Analyst Ratings

The Latest Analyst Ratings for Pliant Therapeutics

By Benzinga Insights

November 10, 5:00 PM

Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

PLRX

2 minute read

Pliant Therapeutics Presentations At The Annual Meeting Of The Society For Immunotherapy Of Cancer Highlight PLN-101095, A Novel Inhibitor Of Integrins αvβ8 And αvβ1

By Benzinga Newsdesk

November 6, 9:52 AM

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, presented three posters

PLRX

1 minute read